People who receive high doses of the chemotherapy drug methotrexate to treat a certain type of brain tumor appear to live longer than people receiving other treatments, according to research published in the January 29, 2008, issue of Neurology.
“Our findings show high-dose methotrexate alone or in combination with other chemotherapy drugs is the most effective treatment available for primary central nervous system lymphoma (PCNSL)” said study author Tracy Batchelor, MD, with the Massachusetts General Hospital Cancer Center in Boston. PCNSL can be a potentially curable brain tumor or one in which there can be a long remission.
The research involved 25 adults with newly diagnosed PCNSL who received a high dose of methotrexate every two weeks for four months or until there were no signs of the brain tumor. The participants were then followed for a minimum of 6.5 years.
The article found 52 percent of the participants achieved complete remission and 40 percent of these patients have not relapsed after an average of seven years. The average survival rate of all participants who received methotrexate was 4.5 years. In contrast, the average survival rate for patients who receive radiation therapy for this type of brain tumor is one year.
“Our findings support the role of methotrexate as a critical chemotherapy drug in the treatment of this type of brain tumor,” said Batchelor. “Moreover, it appears some people may achieve a long remission through the methotrexate alone.”
Batchelor says further studies are needed to identify the optimal methotrexate dose and combination therapy that will produce the most effective results with minimum side effects.
Source: American Academy of Neurology
Related stories:
Nanoparticles carry cancer-killing drugs into tumor cells
Increased efficacy, lower drug toxicity in mice
University of Michigan scientists have created the nanotechnology equivalent of a Trojan horse to smuggle a powerful chemotherapeutic drug inside tumor cells – increasing the drug's cancer-killing activity and reducing its toxic side effects.
Previous studies in cell cultures have suggested that attaching anticancer drugs to nanoparticles for targeted delivery to tumor cells could increase the therapeutic response. Now, U-M scientists have shown that this nanotechnology-based treatment is effective in living animals.
The good news in our DNA: Defects you can fix with vitamins and minerals
As the cost of sequencing a single human genome drops rapidly, with one company predicting a price of $100 per person in five years, soon the only reason not to look at your "personal genome" will be fear of what bad news lies in your genes.
Gene therapy increases survival for end-stage head and neck cancer
A gene therapy invented at The University of Texas M. D. Anderson Cancer Center is the first to succeed in a U.S. phase III clinical trial for cancer, as announced today at the American Society of Gene Therapy annual meeting in Boston.
Chemotherapy-induced anemia increases risk of local breast cancer recurrence
Patients with breast cancer who developed anemia during chemotherapy had nearly three times the risk of local recurrence as those who did not, according to a study published in the April 1 issue of
Clinical Cancer Research, a journal of the American Association for Cancer Research.
Same drug, different results: MUHC researcher on the path to personalized medicine
Minor genetic differences between individuals change the effect of a common medication, study shows
Medicine has moved a little bit closer to the era of tailor-made treatments, based on the unique genetic profiles of individual patients, according to recent research conducted by Dr Rima Rozen of the Research Institute of the McGill University Health Centre (RI MUHC) at the Montreal Children's Hospital and McGill University. Her study, published June 18 in the journal Pharmacogenetics and Genomics, shows how minor genetic differences between individuals alter the way a common drug affects the body.
Increased incidence of melanoma found in rheumatoid arthritis patients treated with methotrexate
A chronic, inflammatory disease of unknown origin, rheumatoid arthritis (RA) affects about 1 percent of adults worldwide. Marked by joint destruction, RA often leads to disability and diminished quality of life. It can also lead to an early death from cancer. Various studies have linked RA to an increased risk of Hodgkin's and non-Hodgkin's lymphoma, leukemia, myeloma, and lung cancer.
Standard chemo works better against metastatic BRCA1/2 breast cancer than against sporadic tumors
The first study to investigate the effects of chemotherapy on metastatic breast cancer in women with the BRCA1 or BRCA2 gene mutation has shown that standard chemotherapy works better in these patients than in women without the BRCA1/2 mutation.
Latest rheumatoid arthritis drugs compared
Findings published today in the open access journal
BMC Musculoskeletal Disorders shows that the latest class of drugs used to treat rheumatoid arthritis (RA) are better than standard anti-inflammatories.